s 2012 0167

The invention relates to medicine, particularly to oncology and can be used for predicting the course of II and III stage malignant melanoma.

According to the invention, the claimed method involves the clinical and paraclinical examination, where are determined the following parameters: clarification of the stage of disease (ST), presence of ulcer formation (U), tumor cell type (TCT), Clark's level of invasion (NI), tumor thickness under Breslow (GT); applied method of treatment (MT) and sex of the patient (SP), then it is calculated the discriminant function (F) by the formula:

$F= -6{,}345 + 1{,}386 \times ST + 4{,}768 \times MT - 2{,}596 \times SP - 3{,}384 \times U + 0{,}806 \times TCT + 1{,}780 \times NI - 1{,}136 \times GT.$

In the case where $F < 0$ is predicted a favorable course of malignant melanoma, and when $F > 0$ – an unfavorable course.

Claims: 1